open access
Ultrasound and cytopathological characteristics of thyroid tumours of uncertain malignant potential — from diagnosis to treatment
- Department of Endocrine Oncology and Nuclear Medicine, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
- Radiology Department II, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
- Institute of Fundamental Technological Research, Polish Academy of Sciences, Warsaw, Poland
- Department of Ultrasound and Mammography Diagnostics, Mazovian Brodnowski Hospital, Warsaw, Poland
- Department of Pathology, Maria Sklodowska-Curie National Research Institute of Oncology, Warszawa, Poland
open access
Abstract
Introduction: The latest World Health Organization (WHO) classification from 2022 distinguishes the division of low-risk thyroid neoplasms such as non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP), follicular tumour of uncertain malignant potential (FT-UMP), and well-differentiated tumour of uncertain malignant potential (WDT-UMP). The final diagnosis is made postoperatively according to histopathologic results. The aim of the study was the assessment of ultrasonographic and cytopathological features of borderline lesions to predict low-risk tumours preoperatively and plan the optimal treatment for that group of patients.
Material and methods: A total of 35 patients (30 women; 5 men), aged 20–81 years with a mean age of 49 years, were enrolled in the study. The study evaluated 35 focal lesions of the thyroid gland, classified as low-risk neoplasms according to the WHO 2022 classification: FT-UMP (n = 21), NIFTP (n = 7), and WDT-UMP (n = 7). Ultrasonographic features of nodules including contrast-enhanced ultrasound (CEUS) and elastography were assessed by 2 specialists, and the risk of malignancy was evaluated according to EU-TIRADS-PL classification.
Results: Of the 35 focal thyroid lesions, most were categorised as low or intermediate risk of malignancy according to EU-TIRADS-PL, with dominant category 3 [n = 13 (37.2%)] and category 4 [n = 15 (42.8%)]. High-risk category 5 was assessed in 7 lesions (20%). In cytopathology nodules were categorised as follows (Bethesda System TBSRTC 2023): Bethesda II (n = 4), Bethesda III (n = 2), Bethesda IV (n = 25), Bethesda V (n = 3), and Bethesda VI (n = 1). In the CEUS study, contrasting patterns dominated compared to the surrounding parenchyma, such as enhancement equal to the parenchyma (66.6%) or intense (28.5%), heterogeneous (61.9%), centripetal (42.8%), or diffuse (57.1%) with fast (33.3%) or compared to parenchyma contrast wash-in (42.8%) and its fast (33.3%) or comparable to thyroid parenchyma wash-out (52.3%).
Conclusions: The study indicates that lesions with uncertain malignant potential typically present features suggesting low to intermediate risk of malignancy based on EU-TIRADS-PL classification, with dominant cytopathologic Bethesda IV category. However, 20% of lesions were assessed tas EU-TIRADS-PL category 5. Low-risk tumours, including NIFTP, FT-UMP, and WDT-UMP, require careful observation and monitoring post surgical treatment due to their potential for recurrence and metastasis. The preoperatively prediction of borderline tumour may play an important role in proper treatment and follow-up.
Abstract
Introduction: The latest World Health Organization (WHO) classification from 2022 distinguishes the division of low-risk thyroid neoplasms such as non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP), follicular tumour of uncertain malignant potential (FT-UMP), and well-differentiated tumour of uncertain malignant potential (WDT-UMP). The final diagnosis is made postoperatively according to histopathologic results. The aim of the study was the assessment of ultrasonographic and cytopathological features of borderline lesions to predict low-risk tumours preoperatively and plan the optimal treatment for that group of patients.
Material and methods: A total of 35 patients (30 women; 5 men), aged 20–81 years with a mean age of 49 years, were enrolled in the study. The study evaluated 35 focal lesions of the thyroid gland, classified as low-risk neoplasms according to the WHO 2022 classification: FT-UMP (n = 21), NIFTP (n = 7), and WDT-UMP (n = 7). Ultrasonographic features of nodules including contrast-enhanced ultrasound (CEUS) and elastography were assessed by 2 specialists, and the risk of malignancy was evaluated according to EU-TIRADS-PL classification.
Results: Of the 35 focal thyroid lesions, most were categorised as low or intermediate risk of malignancy according to EU-TIRADS-PL, with dominant category 3 [n = 13 (37.2%)] and category 4 [n = 15 (42.8%)]. High-risk category 5 was assessed in 7 lesions (20%). In cytopathology nodules were categorised as follows (Bethesda System TBSRTC 2023): Bethesda II (n = 4), Bethesda III (n = 2), Bethesda IV (n = 25), Bethesda V (n = 3), and Bethesda VI (n = 1). In the CEUS study, contrasting patterns dominated compared to the surrounding parenchyma, such as enhancement equal to the parenchyma (66.6%) or intense (28.5%), heterogeneous (61.9%), centripetal (42.8%), or diffuse (57.1%) with fast (33.3%) or compared to parenchyma contrast wash-in (42.8%) and its fast (33.3%) or comparable to thyroid parenchyma wash-out (52.3%).
Conclusions: The study indicates that lesions with uncertain malignant potential typically present features suggesting low to intermediate risk of malignancy based on EU-TIRADS-PL classification, with dominant cytopathologic Bethesda IV category. However, 20% of lesions were assessed tas EU-TIRADS-PL category 5. Low-risk tumours, including NIFTP, FT-UMP, and WDT-UMP, require careful observation and monitoring post surgical treatment due to their potential for recurrence and metastasis. The preoperatively prediction of borderline tumour may play an important role in proper treatment and follow-up.
Keywords
thyroid tumour; ultrasound; thyroid cancer; contrast-enhanced-ultrasound
Title
Ultrasound and cytopathological characteristics of thyroid tumours of uncertain malignant potential — from diagnosis to treatment
Journal
Issue
Article type
Original paper
Pages
170-178
Published online
2024-04-02
Page views
136
Article views/downloads
44
DOI
Pubmed
Bibliographic record
Endokrynol Pol 2024;75(2):170-178.
Keywords
thyroid tumour
ultrasound
thyroid cancer
contrast-enhanced-ultrasound
Authors
Agnieszka Żyłka
Katarzyna Dobruch-Sobczak
Hanna Piotrzkowska-Wróblewska
Maciej Jędrzejczyk
Piotr Góralski
Jacek Gałczyński
Elwira Bakuła-Zalewska
Marek Dedecjus
- Kakudo K. How to handle borderline/precursor thyroid tumors in management of patients with thyroid nodules. Gland Surg. 2018; 7(Suppl 1): S8–SS18.
- Baloch ZW, Asa SL, Barletta JA, et al. Overview of the 2022 WHO Classification of Thyroid Neoplasms. Endocr Pathol. 2022; 33(1): 27–63.
- Rana C, Vuong HG, Nguyen TQ, et al. The Incidence of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features: A Meta-Analysis Assessing Worldwide Impact of the Reclassification. Thyroid. 2021; 31(10): 1502–1513.
- Nikiforov YE, Seethala RR, Tallini G, et al. Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors. JAMA Oncol. 2016; 2(8): 1023–1029.
- Bongiovanni M, Giovanella L, Romanelli F, et al. Cytological Diagnoses Associated with Noninvasive Follicular Thyroid Neoplasms with Papillary-Like Nuclear Features According to the Bethesda System for Reporting Thyroid Cytopathology: A Systematic Review and Meta-Analysis. Thyroid. 2019; 29(2): 222–228.
- Zajkowska K, Kopczyński J, Góźdź S, et al. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features: a problematic entity. Endocr Connect. 2020 [Epub ahead of print]; 9(3): R47–R58.
- Kholová I, Haaga E, Ludvik J, et al. Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features (NIFTP): Tumour Entity with a Short History. A Review on Challenges in Our Microscopes, Molecular and Ultrasonographic Profile. Diagnostics (Basel). 2022; 12(2).
- Rosario PW, Mourão GF, Rosario PW, et al. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features. Endocr Relat Cancer. 2016; 23(12): 893–897.
- Jarząb B, Dedecjus M, Lewiński A, et al. Diagnosis and treatment of thyroid cancer in adult patients - Recommendations of Polish Scientific Societies and the National Oncological Strategy. 2022 Update [Diagnostyka i leczenie raka tarczycy u chorych dorosłych - Rekomendacje Polskich Towarzystw Naukowych oraz Narodowej Strategii Onkologicznej. Aktualizacja na rok 2022]. Endokrynol Pol. 2022; 73(2): 173–300.
- Juhlin CC, Baloch ZW. The 3 Edition of Bethesda System for Reporting Thyroid Cytopathology: Highlights and Comments. Endocr Pathol. 2023 [Epub ahead of print].
- Cibas E, Ali S. The 2017 Bethesda System for Reporting Thyroid Cytopathology. Thyroid. 2017; 27(11): 1341–1346.
- Kuchareczko A, Kopczyński J, Kowalik A, et al. Are molecular tests necessary to diagnose NIFTP? Genes Cancer. 2021; 12: 39–50.
- Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016; 26(1): 1–133.
- Haaga E, Kalfert D, Ludvíková M, et al. Non-Invasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features Is Not a Cytological Diagnosis, but It Influences Cytological Diagnosis Outcomes: A Systematic Review and Meta-Analysis. Acta Cytol. 2022; 66(2): 85–105.
- Ruanpeng D, Cheungpasitporn W, Thongprayoon C, et al. Systematic Review and Meta-analysis of the Impact of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP) on Cytological Diagnosis and Thyroid Cancer Prevalence. Endocr Pathol. 2019; 30(3): 189–200.
- Ito Y, Hirokawa M, Hayashi T, et al. Clinical outcomes of follicular tumor of uncertain malignant potential of the thyroid: real-world data. Endocr J. 2022; 69(7): 757–761.
- Brandler TC, Yee J, Zhou F, et al. Does noninvasive follicular thyroid neoplasm with papillary-like nuclear features have distinctive features on sonography? Diagn Cytopathol. 2018; 46(2): 139–147.
- Song SJ, LiVolsi VA, Montone K, et al. Pre-operative features of non-invasive follicular thyroid neoplasms with papillary-like nuclear features: An analysis of their cytological, Gene Expression Classifier and sonographic findings. Cytopathology. 2017; 28(6): 488–494.
- Yang GCH, Fried KO. Pathologic basis of the sonographic differences between thyroid cancer and noninvasive follicular thyroid neoplasm with papillary-like nuclear features. Ultrasonography. 2018; 37(2): 157–163.
- You SH, Lee KE, Yoo RE, et al. Prevention of total thyroidectomy in noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) based on combined interpretation of ultrasonographic and cytopathologic results. Clin Endocrinol (Oxf). 2018; 88(1): 114–122.
- Yang GCH, Fried KO, Scognamiglio T, et al. Sonographic and cytologic differences of NIFTP from infiltrative or invasive encapsulated follicular variant of papillary thyroid carcinoma: A Review of 179 Cases. Diagn Cytopathol. 2017; 45(6): 533–541.
- Hahn SY, Shin JH, Oh YL, et al. Role of Ultrasound in Predicting Tumor Invasiveness in Follicular Variant of Papillary Thyroid Carcinoma. Thyroid. 2017; 27(9): 1177–1184.
- Rosario PW, da Silva AL, Nunes MB, et al. Risk of Malignancy in Thyroid Nodules Using the American College of Radiology Thyroid Imaging Reporting and Data System in the NIFTP Era. Horm Metab Res. 2018; 50(10): 735–737.
- Hahn SY, Shin JH, Lim HK, et al. Preoperative differentiation between noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) and non-NIFTP. Clin Endocrinol (Oxf). 2017; 86(3): 444–450.
- Boursier L, Clerc Urmes I, Garon J, et al. Ultrasound and cytological characteristics of non-invasive follicular thyroid neoplasm with papillary-like nuclear features compared to papillary carcinomas. Ann Endocrinol (Paris). 2020; 81(1): 28–33.
- Săftoiu A, Gilja OH, Sidhu PS, et al. The EFSUMB Guidelines and Recommendations for the Clinical Practice of Elastography in Non-Hepatic Applications: Update 2018. Ultraschall Med. 2019; 40(4): 425–453.
- Garino F, Deandrea M, Motta M, et al. Diagnostic performance of elastography in cytologically indeterminate thyroid nodules. Endocrine. 2015; 49(1): 175–183.
- Stoian D, Borcan F, Petre I, et al. Strain Elastography as a Valuable Diagnosis Tool in Intermediate Cytology (Bethesda III) Thyroid Nodules. Diagnostics (Basel). 2019; 9(3).
- Sidhu PS, Cantisani V, Dietrich CF, et al. The EFSUMB Guidelines and Recommendations for the Clinical Practice of Contrast-Enhanced Ultrasound (CEUS) in Non-Hepatic Applications: Update 2017 (Long Version). Ultraschall Med. 2018; 39(2): e2–e44.
- Trimboli P, Castellana M, Virili C, et al. Performance of contrast-enhanced ultrasound (CEUS) in assessing thyroid nodules: a systematic review and meta-analysis using histological standard of reference. Radiol Med. 2020; 125(4): 406–415.
- Xu Y, Qi X, Zhao X, et al. Clinical diagnostic value of contrast-enhanced ultrasound and TI-RADS classification for benign and malignant thyroid tumors: One comparative cohort study. Medicine (Baltimore). 2019; 98(4): e14051.
- Zhang YZ, Xu T, Gong HY, et al. Application of high-resolution ultrasound, real-time elastography, and contrast-enhanced ultrasound in differentiating solid thyroid nodules. Medicine (Baltimore). 2016; 95(45): e5329.
- Nikiforov YE, Baloch ZW, Hodak SP, et al. Change in Diagnostic Criteria for Noninvasive Follicular Thyroid Neoplasm With Papillarylike Nuclear Features. JAMA Oncol. 2018; 4(8): 1125–1126.